Understanding Brain Activity in Neurodiverse Individuals Using EEG for Better Diagnosis and Support

Comparative Analysis of Standardized Clinical Assessment Tools and NEMA AI EEG-based Cognitive Evaluation for Neurodiverse Populations - Case Control Study - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086198

Enrollment

150

Registered

2025-05-02

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F70- Mild intellectual disabilities

Interventions

Intervention1: NEMA AI EEG Scan Insights: NEMA AI offers a non-invasive, AI-driven EEG-based neurocognitive mapping tool, which serves as both a diagnostic aid and a personalization engine. How It Wo

Eligibility

Inclusion criteria

Inclusion criteria: Children within the age group of 4-18 Diagnosed with ASD, ADHD, or learning disabilities based on DSM-5 criteria Participants.

Exclusion criteria

Exclusion criteria: a. Children with neurological disorders (e.g., epilepsy) affecting EEG outcomes Uncorrected hearing or vision impairments. b. Non cooperative child even after consent taken will be excluded.

Design outcomes

Primary

Measure	Time frame
To evaluate the reliability and validity of NEMA AI s EEG-based assessments in measuring cognitive and neurodevelopmental profiles in neurodiverse individuals, by comparing its outputs with standardized tools like WISC, Conners, and DSM-5-based evaluations to establish alignment with clinically accepted benchmarks.Timepoint: Baseline (Week 0, Day 1): EEG + traditional clinical/psychometric assessment. Week 4: Mid-point reassessment for progress tracking and consistency check. Week 8: Final reassessment to measure improvements and validate longitudinal reliability and efficacy.	—

Measure

Time frame

To evaluate the reliability and validity of NEMA AI s EEG-based assessments in measuring cognitive and neurodevelopmental profiles in neurodiverse individuals, by comparing its outputs with standardized tools like WISC, Conners, and DSM-5-based evaluations to establish alignment with clinically accepted benchmarks.Timepoint: Baseline (Week 0, Day 1): EEG + traditional clinical/psychometric assessment. Week 4: Mid-point reassessment for progress tracking and consistency check. Week 8: Final reassessment to measure improvements and validate longitudinal reliability and efficacy.

—

Secondary

Measure	Time frame
1. To compare the screening accuracy of NEMA AI EEG with traditional standardized clinical tools.Timepoint: 4 Weeks comparison on improvement & therapy creations based on input.	—

Countries

India

Contacts

Public ContactNidhi Nidhi

Cradle Children Hospital

getsunil7@gmail.com83022 22120

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026